Skip to main content
StemRIM Inc. logo

StemRIM Inc. — Investor Relations & Filings

Ticker · 4599 ISIN · JP3399690001 T Professional, scientific and technical activities
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-03-12 Regulatory Filings
Country JP Japan
Listing T 4599

About StemRIM Inc.

https://stemrim.com/english/

StemRIM Inc. is a biotechnology company developing a next-generation category of regenerative medicine called “Regeneration-Inducing Medicine™”. This innovative approach aims to treat intractable diseases and injuries by maximizing the body's innate tissue repair capabilities. The core mechanism of action involves mobilizing a patient's own endogenous stem cells to damaged tissues to induce functional regeneration, a method distinct from conventional cell-therapy. The company's research and development focuses on creating new drugs based on this novel mechanism, with applications including gene therapy for rare skin diseases such as dystrophic epidermolysis bullosa.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 21
2026-03-12 Japanese
半期報告書－第21期(2025/08/01－2026/07/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MD&A), and corporate information for the interim period (2025-08-01 to 2026-01-31). This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2026
2026-03-12 Japanese
有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 1% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kinki Local Finance Bureau by StemRIM Inc. It details the issuance of new shares as part of a restricted stock compensation plan for directors and auditors. This type of filing is a formal regulatory document concerning capital changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-11-12 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It serves as a formal declaration by the CEO regarding the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). Since it is a regulatory filing required by law to accompany the annual report and does not fit into the specific categories of financial reports or announcements, it is classified as a Regulatory Filing (RNS). FY 2025
2025-10-21 Japanese
有価証券報告書－第20期(2024/08/01－2025/07/31)
Annual Report Classification · 1% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) for StemRIM Inc., covering the fiscal year from August 1, 2024, to July 31, 2025. This is the standard Japanese regulatory filing equivalent to a 10-K, containing comprehensive financial statements, business descriptions, and management analysis. It is not a mere announcement or certification, but the full report itself. FY 2025
2025-10-21 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 1% confidence The document is a 'Temporary Report' (臨時報告書) filed with the Kinki Finance Bureau in Japan. It details the issuance of stock options (new share acquisition rights) to company directors. This type of filing is a standard regulatory disclosure in Japan for significant corporate events such as capital changes or equity-based compensation, which falls under the 'Regulatory Filings' (RNS) category as it is a specific statutory filing that does not fit into the other specialized categories like 'Share Issue' (which usually refers to public offerings) or 'Director's Dealing' (which refers to trading).
2025-09-12 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.